after signing the consent form, you are assigned a study number and placed into one of two groups: the mk-1045 group or the blinatumomab group. the assignment is done by a computer program and you do not choose the group.

if you are in the mk-1045 group, the drug is given by intravenous infusion. the product is described as a solution for infusion with a dose listed as 0 % (v/v) (percent volume/volume).

if you are in the blinatumomab group, the drug is given by intravenous infusion at a dose of 28 µg (microgram) per administration.

while the infusion is running, clinical staff check your vital signs, blood counts, and other laboratory values at regular intervals.

any signs of an adverse event (for example, fever, low blood pressure, or allergic reaction) are recorded and reported.

after each treatment cycle, doctors evaluate whether a complete remission (cr) has been achieved. the evaluation includes bone‑marrow testing and other standard examinations.

the primary focus is on the first three cycles; response data from these cycles determine the primary outcome of the study.

throughout the study, all adverse events are recorded, and the number of participants who discontinue the medication because of an adverse event is tracked.

laboratory tests and physical examinations are performed regularly to assess tolerability.

based on the response assessment and safety evaluation, you may continue receiving the assigned medication for additional cycles or stop treatment if the medication is not effective or if side effects are unacceptable.

after the treatment period ends, you are followed for overall survival, which measures the length of time you remain alive after starting the study medication.

follow‑up visits may include clinic assessments and collection of survival data.